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Abstract
Background: Tumor heterogeneity in breast cancer tumors is today widely recognized. Most of the available
knowledge in genetic variation however, relates to the primary tumor while metastatic lesions are much less
studied. Many studies have revealed marked alterations of standard prognostic and predictive factors during
tumor progression. Characterization of paired primary- and metastatic tissues should therefore be fundamental
in order to understand mechanisms of tumor progression, clonal relationship to tumor evolution as well as the
therapeutic aspects of systemic disease.
Methods: We performed full exome sequencing of primary breast cancers and their metastases in a cohort of
ten patients and further confirmed our findings in an additional cohort of 20 patients with paired primary and
metastatic tumors. Furthermore, we used gene expression from the metastatic lesions and a primary breast
cancer data set to study the gene expression of the AKAP gene family.
Results: We report that somatic mutations in A-kinase anchoring proteins are enriched in metastatic lesions. The
frequency of mutation in the AKAP gene family was 10% in the primary tumors and 40% in metastatic lesions.
Several copy number variations, including deletions in regions containing AKAP genes were detected and showed
consistent patterns in both investigated cohorts. In a second cohort containing 20 patients with paired primary and
metastatic lesions, AKAP mutations showed an increasing variant allele frequency after multiple relapses. Furthermore,
gene expression profiles from the metastatic lesions (n = 120) revealed differential expression patterns of AKAPs relative
to the tumor PAM50 intrinsic subtype, which were most apparent in the basal-like subtype. This pattern was confirmed
in primary tumors from TCGA (n = 522) and in a third independent cohort (n = 182).
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Conclusion: Several studies from primary cancers have reported individual AKAP genes to be associated with cancer
risk and metastatic relapses as well as direct involvement in cellular invasion and migration processes. Our findings
reveal an enrichment of mutations in AKAP genes in metastatic breast cancers and suggest the involvement of AKAPs
in the metastatic process. In addition, we report an AKAP gene expression pattern that consistently follows the tumor
intrinsic subtype, further suggesting AKAP family members as relevant players in breast cancer biology.
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Background
The mutational landscape of primary breast cancer tu-
mors has been extensively studied in recent years and a
large number of exomes and full genomes have become
available [1–3]. Most studies to date have focused on the
primary breast tumor whilst mutational profiles of meta-
static lesions and their relationship to the primary tumor
have largely been lacking. This has important clinical
implications as altered receptor status in the metastatic
lesion has been shown to occur at high rates ranging
from 14.5–40% for ER 40% for PgR and 0–37% for
HER2-receptors during cancer progression [4–6] and is
additionally affected by adjuvant therapy with major im-
plications for management of the metastatic disease. The
genetic evolution and accumulation of genetic aberra-
tions in metastatic malignancies has been described in
[7–13]. Most importantly, accumulation of activating es-
trogen receptor 1 (ESR1) mutations in metastatic lesions
has demonstrated a mechanism of acquired hormone re-
sistance in metastatic breast cancer [14–16].
In order to characterize the mutational landscape in
primary tumors and metastases, we performed exome
sequencing in ten patients for which paired samples
were available. We found a pronounced heterogeneity
both between and within patients with a general enrich-
ment in number of somatic mutations in metastatic tis-
sues. As a consequence of finding a number of both
silent and nonsilent mutations in the AKAP9 gene, one
of the recurrent cancer genes in the COSMIC data base,
we investigated all 14 AKAP (A-kinase anchoring pro-
teins) family members and found somatic mutations in
seven of them, the majority of which were in metastatic
lesions only. In addition, several copy number changes
were present in AKAP loci, mostly deletions. The dif-
ferent members of the A-kinase anchoring proteins
(AKAPs) directs and orchestrates the activity of Protein
Kinase A (PKA), which is an important factor in cell
motility and proliferation [17]. In line with the cellular
function of PKA, several of the AKAP members have
been associated with cancer development and metastatic
spread. TCGA data confirms the presence of AKAP
somatic point mutations in primary breast cancer with a
prevalence of 7% and with a higher rate including copy
number variations.
Methods
Patient population and ethics
Ten patients representing different clinical subtypes and
metastatic lesion sites were included in the study
(Table 1). Patients P1 to P7 were part of the Swedish
multicenter trial TEX, ClinicalTrials.gov identifier
NCT01433614 that enrolled 287 patients with loco-
regional or distant breast cancer relapse from 2002 until
2007 [18]. Patients P8 to P10 were part of a prospective
biopsy study at Radiumhemmet Karolinska Hospital dur-
ing 2007–2010. The information on primary and relapse
ER, PR and HER2 status were retrospectively collected
from pathology reports and reassessed by IHC/ICC. All
patients were given informed consent.
Patients for cohort 2 (Additional file 1: Table S1) were
identified using search criteria in the digital patient rec-
ord system which allowed collection of formalin-fixated
paraffin-embedded (FFPE) material from primary breast
cancer, local recurrence, axillary- and distant metastases
as well as clinical information as described in Ullah et al.
(submitted). Samples were obtained only after approval
by the Ethical committee at Karolinska Institutet,
Stockholm. Samples were further investigated and
assessed by a certified surgical pathologist. All studies
were approved by the Regional Ethical Review Board in
Stockholm, Sweden.
Cohort 1: DNA extraction and exome capture
DNA was extracted from fresh frozen fine needle aspir-
ation (fnac) biopsies (metastases), fresh frozen surgical ma-
terial (primary tumors) and blood (germline control),
concentrations were determined using Qubit dsDNA HS
assay (Life Technologies). Due to low concentrations ob-
tained from aspirations, we used WGA in order to meet
the required amounts of DNA needed for exome enrich-
ment. All paired samples including germline DNA were
subjected to WGA using GenomiPhi V2 DNA Amplifica-
tion Kit (GE Healthcare) according to manufacturer’s in-
structions, a summary of DNA concentrations can be
found in Additional file 2: Table S2. The fragment length
after ultrasonic DNA fragmentation by Covaris (LGC Gen-
omics) was measured using 2200 TapeStation Genomic
DNA screen tape (Agilent Technologies), amplified DNA
did not differ from non-amplified DNA (data not shown).
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Exome capture from amplified tumor and normal
DNA was performed using Sure Select Human All Exon
V4 (Agilent Technologies) according to the SureSelectXT
Target Enrichment System for Illumina Paired-End
Sequencing manual version 1.3. Sample preparation,
hybridization and post-hybridization amplification were
performed according to the manufacturers instructions,
with five cycles of PCR in amplification of adaptor-
ligated library, and 12 cycles in the post-hybridization
captured library amplification step. The quality of final
libraries was evaluated using TapeStation High Sensiti-
vity DNA kit (Agilent) and the libraries were quantified
using KAPA SYBR® FAST ABI Prism qPCR Kit (KAPA
Biosystems). Enriched exome fragments were pooled
and paired-end sequenced on a HiSeq 2000 platform
(Illumina).
Cohort 1: Variant detection
Demultiplexing, alignment and variant detection were
carried out using the Casava 1.8.2 pipeline from Illumina
with default parameters and duplicate removal. Samtools
v0.1.9 (r783) was used to create mpilups from the bam
files and variant identification was performed using the
VarScan (v2.3.2) [19] somatic function with default pa-
rameters, but a minimum variant frequency of 5% and a
somatic P value of 0.2. The VarScan-identified positions
were examined using the Ensembl variant prediction
tool (v 2.6 and database ver 69) and known SNPs were
labeled using the SnpEff database (SnpSift version 1.9c).
The VarScan, Variant effect prediction, SnpEff and mpi-
leup base count outputs were joined on position using in-
house scripts to facilitate downstream filtering and com-
parison. The output data was filtered by retaining only
those positions with variant frequency in germline sample
< 1%, variant reads in tumor ≥ 5, and total coverage > 30.
Average coverage per exome was 47.3 Mb (range 18.8–
51.1 M) (Additional file 3: Figure S2a). SNVs, CNVs and
LOH were called by comparative analysis of sequence var-
iants between tumor and germline samples. To account
for potential false positive mutation calls, the output data
was manually filtered and positions with variant frequency
in germline sample < 1%, variant reads in tumor < 5 and a
total coverage of < 30 reads were excluded, leaving only
exome wide mutations with an VAF > 16%.
To focus the analysis, a set of 505 recurrently mutated
genes was used to select somatic variant positions of inter-
est. For these genes, all variant positions occurring in the
pairs of primary and metastatic lesions were selected, in-
cluding those with less than five tumor variant reads, not
to exclude true shared low frequency mutations. The se-
lected positions were manually investigated, visualizing
the unfiltered reads in Integrative Genomics Viewer
(Broad Institute) with respect to alignment quality, base
quality of variant base, read direction and total coverage
on the position. Variant positions with the following con-
ditions were manually removed from the data set: variant
reads in normal sample, poor alignment or highly variable
sequences and variant reads in one direction only.
Table 1 Clinical information cohort 1
Patient ID Sample PAM50 subtype ER PR HER2 HER2 CNV (exome data) AdjCT AdjHT AdjRT DFI Relapse site Relapse to death
P1 Primary Tumor
Metastasis
3 NA
Luminal B
+
-
+
-
-
-
HER2-
HER2-
+ + + 3.3 liver 3.2
P2 Primary Tumor
Metastasis
3 NA
Basal like
-
NA
-
NA
-
NA
HER2-
HER2-
+ – + 1.4 lymph 4.9
P3 Primary Tumor
Metastasis
3 Na
Luminal B
-
-
+
-
-
NA
HER2-
HER2-
– – + 4.1 liver 1.5
P4 Primary Tumor
Metastasis
3 NA
Basal like
-
NA
-
NA
NA
NA
HER2+ (CN 3.5)
HER2+ (CN 3.5)
+ + + 8.1 lung 6.0
P5 Primary Tumor
Metastasis
N/
A
NA
Luminal A
+
+
-
-
-
NA
HER2-
HER2+ (CN 2.5)
– + + 3.5 liver 5.7
P6 Primary Tumor
Metastasis
3 NA
HER2 enriched
+
+
+
-
NA
-
HER2-
HER2-
+ + + 2.6 lymph 1.1
P7 Primary Tumor
Metastasis
2 NA
Normal like
+
+
+
-
NA
-
HER2-
HER2-
+ + + 4.8 skin 0.8
P8 Primary Tumor
Metastasis
NA
NA
+
+
+
+
-
-
HER2+ (CN 2.4)
HER2- (CN 0.8)
+ + + 5a liver 0.7
P9 Primary Tumor
Metastasis
NA
NA
-
-
-
-
NA
-
HER2-
HER2-
+ – + 11a breast NA
P10 Primary Tumor
Metastasis
NA
NA
+
+
+
+
-
-
HER2-
HER2-
+ + + 4a bone 0.4
Receptor status by IHC (immunohistochemistry)
ER estrogen receptor, PR progesteron, HER2 Her2 receptor status, HER2 CNV amplification of Her2 derived from exome data, AdjCT adjuvant chemotherapy, AdjHT
adjuvant hormone therapy, AdjRT adjuvant radiotherapy, DFI disease free interval (months); Relapse to death (months)
aapproximated as time from primary tumor surgery date to relapse diagnosis date
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Cohort 2: DNA extraction and exome capture
We used additional exome sequences available from
paired primary and metastatic samples from 20 patients
to test our findings from cohort 1 (Additional file 1:
Table S1). DNA isolation, exome capture and sequencing
was performed by SeqWright Genomic Services (GE
Healthcare, Houston, USA). DNA was isolated from
serial thick sections of FFPE tissues using a QIAamp
DNA FFPE Tissue Kit (Qiagen, CA, USA) a summary
of DNA concentrations can be found in Additional file 2:
Table S2. DNA from normal axillary lymph nodes FFPE
tissues was used as germline controls. In all cases we
followed the manufacturer’s recommended protocol.
Exome capture was performed using Sure Select XT2
Human All ExonV5 (Agilent Technologies) according
to manufacturers instructions. Paired end sequencing
was performed on Illumina HiSeq 2500.
Cohort 2: Variant detection
Raw sequencing reads were quality and adapter
trimmed using trim_galore, where the first 13 bases of
Illumina adapter were used and stringency parameter
was set to 2. Reads having lengths less than 70 after
trimming were filtered out with their paired mates.
Trimmed reads were aligned to the human reference
genome build hg19 using bwa-mem with default pa-
rameters. The aligned reads were marked for duplicates
by Picard (25%), realigned around known indels and
base-quality recalibrated by GATK. Somatic single nu-
cleotide variants (SNVs) were detected by Mutect [20]
with the high-confidence mode. Copy number alter-
ations were detected by ADTEx [21]. All pipelines and
analyses were run using Anduril [22], a workflow
framework for scientific data analysis. Mean coverage
per sample is given in (Additional file 3: Figure S2b).
CNV calculations
Copy number variations (CNVs) were determined by
calculating the normalized read coverage at each SNP
position for paired tumor and germline samples, then
taking the log2 of the ratio of these numbers and recen-
tering to zero. In Additional file 4: Figure S1a-b, these
measures were plotted as a moving average across ten
adjacent SNPs.
LOH calculations
Estimating LOH fraction and tumor content using a
Beta-Normal mixture model Additional file 5: Figure
S3a-b. Histograms show the distribution of major allele
frequencies (range: 50–100%) and red curves show the
mixture model estimated from the data. The set of SNPs
called in the germline sample was considered in the tumor
sample (primary and metastasis independently). When
genomes contain regions of LOH, the distribution will be
bimodal, as illustrated in the inset (top right). The first
component (closer to 50%; red in inset) represents hetero-
zygous SNPs in regions without LOH and was modeled as
a normal distribution with a mean close to 50% in a per-
fect sample, but will increase towards 100% as allelic drop-
out increases.
The second component (closer to 100%; blue in inset)
represents homozygous SNPs in regions with LOH, was
modeled as a beta distribution with two parameters (the
mean of this component should be close to 100% and
increase as LOH fraction increases and decrease as with
non-cancer cell contamination. The mixture distribution
thus had four free parameters plus the mixture propor-
tion, the latter representing the estimated LOH fraction
of the sample. Fitting this mixture to the observations
yielded estimates for LOH fraction, tumor fraction and
allelic dropout rate for each sample (Additional file 5:
Figure S3). Model fitting was performed using the
EstimatedDistribution function of Mathematica 9.0
(Wolfram Research Inc.).
Microarray
Microarray experiment was performed as follows; total RNA
from frozen metastatic tumors was extracted using the Qia-
gen RNeasy Mini Kit (Qiagen, Germany). All patient tumor
samples were profiled using NuGEN amplification protocol
and hybridized using the HRSTA-2.0 custom human Affy-
metrix array GPL10379. The microarray gene expression
analyses were performed in R using the aroma.affymetrix
package. The PAM50 intrinsic subtypes (PAM50) for cohort
1 relapses have been previously published [23] and publicly
available GSE56493. The case-control cohort have been pre-
viously published [24] GSE48091. The normalized expres-
sion array and intrinsic subtype calls for the TCGA data
were taken from the original manuscript [1].
Control experiment
To control for amplification-induced artefacts i.e. false posi-
tive and false negative mutation rates, we designed a con-
trol experiment as follows: Genomic DNA from a healthy
individual was extracted from whole blood using the
PAXgene Blood DNA kit (Qiagen). The DNA was of good
quality (> 58 kB fragment length) and of high concentration
(> 300 ng/uL). This DNA was diluted 1:100 and 1:1000 and
6 ng respectively 0.6 ng was subjected to WGA, exome
enriched, sequenced and analyzed as described above
using an unamplified sample as ‘germline’ control,
(Additional file 6: Table S3).
Results
We first analyzed somatic mutations in a set of 505 previ-
ously recognized recurrent cancer genes from COSMIC
census database and The Cancer Genome Atlas [1]
Kjällquist et al. BMC Cancer  (2018) 18:174 Page 4 of 17
(henceforth called ‘recurrent cancer genes’) where an en-
richment for true driver mutations may be expected. We
detected a total of 654 somatic mutations, of which 301
were nonsynonymous, distributed over 190 different genes.
Of nonsynonymous mutations, an average of 43 and 47%
were predicted to be deleterious and tolerated, respectively.
The number of somatic mutations was significantly
different between primary tumor and metastatic lesion
The mutational load was significantly greater in metas-
tases, both in recurrently mutated genes, (average: 6,
range: 0–20 vs average: 24, range: 2–58; p < 0.001;
Student’s t test) (Fig. 1a) and in all exomic regions (aver-
age: 222, range: 11–825 vs average: 706, range: 51–1411;
p < 0.05; Student’s t-test) (Fig. 1b). In eight of the patients,
the metastatic lesions showed a higher number of somatic
point mutations than the primary tumor (range: 2–19 fold
higher). Interestingly, in two of the patients (patients P6
and P7) the relationship was inverted, with fewer muta-
tions in recurrently mutated genes in the metastatic tissue
(Fig. 1a; 2.3 and 7 fold fewer) and (Fig. 1b; 3 and 10 fold
fewer). The lower number of mutations in these metasta-
ses coincided with a reduced level of CNV and LOH in
these two patients (Additional file 4: Figure S1b). This un-
expected pattern was also seen in five of 20 patients in co-
hort 2 (data not shown). The number of shared mutations
varied between 0 and 47 (average 15.4) in whole exomes
and included potential driver genes PDGFR, TP53, DAXX,
ERBB2, FBOXO11 and JAK3 (Fig. 1c). Despite the small
cohort we found several mutations in previously described
genes, frequently mutated in breast cancer [1–3] (Table 2).
Importantly, no recurrent cancer genes were found mu-
tated in the control experiment.
Both single-nucleotide variants (SNVs), copy-
number variants (CNVs) and loss-of-heterozygosity
(LOH) patterns support a finding of pronounced
heterogeneity both within and between patients
(Additional file 4: Figure S1a-b).
Ti/Tv
The average Ti/Tv ratio for the heterozygous SNPs for
each exome in cohort 1 was 2.7 (2.6–2.8) and for exome
wide variant positions 3.37 and 7.7 in the primary tumor
samples and the metastatic samples respectively (p < 0.05).
The high Ti/Tv ratios in especially metastatic samples is
likely a result of the predominance of C > T/G > A, which
can be seen among the AKAP mutations (Tables 1 and 2).
These substitutions are enriched in a majority of can-
cers and could be associated with the age at cancer
diagnosis as well as adjuvant chemotherapy using alkyl-
ating drugs or adjuvant radiotherapy [25]. The Ti/Tv ra-
tio are further known to be elevated in breast cancer,
were a bias towards TpC mutation hotspots as well as a
gene expression related bias towards A > G transitions
compared to T > C transitions in coding strand and
have been reported [26]. Specifically in breast cancer,
mutational signatures clearly shows a predominance of
C > T mutations, with possible associations to the ageing
processes and APOBEC-induced mutagenesis [25, 27].
Interestingly, we have discovered a significant enrichment
of the APOBEC related mutational signature among the
metastatic tumors in cohort 2 (Ullah et al. submitted),
which is in support of the high level of Ti/Tv ratio in
metastatic lesions of cohort 1. A similar, enrichment of
the APOBEC signature in metastatic breast cancer has
also been reported by others [28].
Mutations in the AKAP gene family are enriched in
metastases
While investigating the list of recurrently mutated can-
cer genes we found that AKAP9 carried an unexpected
number of both silent and nonsilent mutations in the
metastatic lesions. Because of the previously reported
implication of AKAP9 in breast- and other cancers, the
analysis was extended to include all members of the
AKAP gene family. We found a striking enrichment of
mutations in the family of A-kinase anchoring proteins
(AKAPs) in metastatic samples (p < 0.02; Fisher’s exact
test) compared with primary lesions. Altogether nonsy-
nonymous coding mutations were found in seven of the
AKAP family members AKAP5, AKAP6, AKAP8,
AKAP9, AKAP10, AKAP12, AKAP13 (Table 3). Out of
the ten patients in the first cohort, five (50%) carried
mutations in AKAP genes in only metastatic tissue
(four) or in only the primary lesion (one). Out of the
total nine AKAP mutations recorded, eight were found
uniquely in the metastatic lesions, indicating that these
mutations have emerged in a subclone during late pri-
mary tumor evolution. None of the “metastatic-unique”
mutations could be found in the corresponding primary
tumors, even at low allele frequency levels.
We next wanted to investigate this interesting muta-
tion pattern in an independent cohort available in our
lab. This cohort consists of 20 patients with paired pri-
mary breast tumor and multiple metastatic sites and is
comparable regarding tumor grade, treatment and
survival (Additional file 1: Table S1). Out of the 20
additional patients, four (20%) carried mutations in
AKAP genes (AKAP3, AKAP4, AKAP9, AKAP11) in
both primary tumor and metastatic tissue or in only the
metastatic lesion (Table 4). In total four nonsynonymous
mutations were recorded, two of these were only found
in the corresponding metastatic lesion. The enrichment
of mutations in metastases was not significant in cohort
2 (Fisher’s exact test), possibly because of the small size
of the cohort. However, in the two patients (patients 7
and 19) having a low VAF in the primary tumors there
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Fig. 1 a Number of nonsynonymous somatic mutations in recurrently mutated cancer genes. Mutations in genes previously reported mutated in
different cancers (COSMIC). The primary tumors and metastases carried an average of 6 (range: 0–20) and 24 (range: 2–58) nonsynonymous
mutations respectively (p< 0.001; Student’s t-test). b Number of nonsynonymous somatic mutations in all captured exomic regions. Primary tumors
showed an average of 222 nonsynonymous mutations (range: 11–825) whereas the mutational load in metastases was significantly greater in metastases
(average: 706, range: 51–1411; p< 0.05; Student’s t-test). c Number of somatic mutations shared in primary tumor and its corresponding metastatic
lesion. All variant positions occurring in the pairs of primary and metastatic lesions were selected including those with less than 5 tumor variant reads.
The positions were manually investigated as described in methods section
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was an increase of allele frequency in the metastatic le-
sions. The same increase was seen in two of the patients
having multiple relapses from different time points (pa-
tient 19 and 8), indicating clonal selection. In all four pa-
tients the tumor cell fraction was over 80% in the
metastatic samples. In patient 19 however, tumor cell
content was as low as 20% in the primary tumor, pos-
sibly leading to an underestimation of variant allele fre-
quency. This highlights the possible role of AKAP
deregulation in the oncogenic and metastatic setting
discussed in [29–31].
The protein structures of mutated AKAPs are sum-
marized in Fig. 2 including the functional protein kin-
ase interaction domains (PKA-RI/II, PKC) from the
UniprotKB database and [32]. None of the reported
mutations were located within the PKA-binding do-
mains although metastatic mutations in AKAP9
(S2518 N) and AKAP13 (D477N) were located within
a 20 a.a from the domain. AKAP10 mutation L182P
is located within one of the regulator of G-protein
signaling (RGS1) motif [33]. Interestingly, the AKAP8
(Q169X) mutation is located within the MCM2 bind-
ing region (see discussion), and the two AKAP12 mu-
tations were found in a proposed EGFR interacting
domain [34].
AKAP cytogenetics
Several copy number variations (CNV) in regions contain-
ing AKAP genes were detected. AKAP7 and AKAP12,
both located on chromosome 6 at 130.5 and 151 Mbp re-
spectively, were deleted in both primary tumor and metas-
tasis in two of the patients (P1, P5). In patient P2 the
AKAP7 and AKAP12 deletion was aquired in the metasta-
sis (Table 5). One patient carried deletions in both primary
tumor and metastasis in a chromosome 13 region con-
taining AKAP11 (P1) and two additional patients seemed
to have aquired the deletion in the metastasis (P3 and P8).
In patient P4 AKAP8 (chr 19) was amplified in the metas-
tasis but also had aquired a deleterious nonsense muta-
tion. The same patient also showed a focal amplification
in chromosome 17 involving AKAP1.
The second cohort showed similar CNV patterns for
AKAP1 and AKAP12. AKAP1 was amplified in both pri-
mary and metastasis in ten of the 20 patients. Interest-
ingly, AKAP1 amplifications was the most frequent
mutation in the Breast Invasive Carcinoma TCGA data
set altered in 8% of the tumors (n = 1098), data from
cbioportal.org (Additional file 7: Figure S4b).
AKAP12 was deleted in both primary and corre-
sponding metastasis in two patients and in one pa-
tient the 6q25.1 deletion was aquired in the
metastatic lesion. Loss of AKAP12 has been shown to
increase cancer incidence and metastatic spread in
several cancers including prostate [35, 36] and breast
cancer [37].
AKAP gene expression
As some of the AKAP members are reported with al-
tered gene expression levels in the literature [38, 39] we
Table 2 Most frequently mutated genes in cohort1 sorted by
occurrence in metastases
Metastasis
n = 10 (%)
Primary tumors
n = 10 (%)
Primary tumors
TCGA (%)
KMT2C 6 (60) 1 (10) 8
AFF2 3 (30) 3 (30) 2
KMT2A 3 (30) 1 (10) 2
MED12 3 (30) 1 (10) 2
ASXL1 3 (30) 1 (10) 1
FBXO11 3 (30) 0 1
TP53 2 (20) 1 (10) 35
ARID1A 2 (20) 1 (10) 4
NF1 2 (20) 1 (10) 3
AKAP13 2 (20) 0 2
APC 2 (20) 1 (10) 2
ARID1B 2 (20) 1 (10) 2
ATRX 2 (20) 1 (10) 2
CDK12 2 (20) 0 2
KDM6A 2 (20) 0 2
CDH1 1 (10) 0 7
PIK3CA 0 1 (10) 36
AKAP12 2 (20) 0 1
ALK 2 (20) 1 (10) 1
ARID2 2 (20) 1 (10) 1
BAP1 2 (20) 0 1
CAMTA1 2 (20) 1 (10) 1
CLTC 2 (20) 0 1
DICER1 2 (20) 0 1
EML4 2 (20) 0 1
EPS15 2 (20) 0 1
GNAS 2 (20) 0 1
KDM5A 2 (20) 1 (10) 1
KDR 2 (20) 0 1
MET 2 (20) 0 1
MYH11 2 (20) 0 1
NIN 2 (20) 0 1
NUMA1 2 (20) 0 1
NUP98 2 (20) 0 1
PCSK7 2 (20) 3 (30) 1
PDGFRB 2 (20) 1 (10) 1
Number of mutated samples n = 10, (%). The third column lists the reported
mutation frequencies in TCGA breast cancer [1]
MET metastasis, PT primary tumor, TCGA the cancer genome atlas
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Table 3 List of AKAP nonsynonymous somatic mutations in cohort 1
Gene Position CytoBand Mutation Exon A.A substitution Protein region SIFT Prediction Primary VAF Metastasis VAF Patient
AKAP1
AKAP2
AKAP3
AKAP4
AKAP5 chr14:64935761 14q23 G > A 2/2 Asp217Asn NA damaging 5.2% 0% P2
AKAP6 chr14:33293693 14q12 G > A 13/14 Gly2225Glu NA tolerated 0% 17% P1
AKAP7
AKAP8 chr19:15484018 19q13.12 G > A 1/11 Gln169X MCM2 binding
domain
nonsense 0% 15% P4
AKAP9 chr7:91708964 7q21.2 G > A 31/50 Ser2518Asn close to PKA-R
domain
tolerated 0% 9% P1
AKAP10 chr17:19861659 17p11.2 A > G 4/15 Leu182Pro RGS1 binding
domain
damaging 0% 16% P1
AKAP11
AKAP12 chr6:151670403
chr6:151671474
6q25.1 G > A
G > A
4/5
4/5
Gly293Arg
Ala650Thr
EGFR interaction
domain
EGFR interaction
domain
damaging
damaging
0%
0%
22%
15%
P5
P10
AKAP13 chr15:86124141
chr15:86122728
15q25.3 C > T
G > A
7/15
7/15
Gln948X
Asp477Asn
NA
close to
PKA-RII domain
nonsense
damaging
0%
0%
10%
16%
P4
P5
AKAP14
VAF variant allele frequency; Protein region: Approximate relation to functional domains (see Fig. 2 for details). No tumor cell fraction was available for cohort 1.
SIFT prediction
Table 4 List of AKAP nonsynonymous somatic mutations in cohort 2
Gene Position CytoBand Mutation Exon A.A
substitution
Protein
region
SIFT
Prediction
Primary
VAF
Axillary
lymph VAF
Metastasis
1 VAF
Metastasis
2 VAF
Patient
AKAP1
AKAP2
AKAP3 chr12:4725047 12p13.32 G > A 5/5 Ser807Leu NA damaging 2% – 13% 41%,
22%a
pat 19
AKAP4 chrX:49958130 Xp11.22 A > G 5/6 Phe412Leu NA damaging 0% 0% 22%b 26% pat 8
AKAP5
AKAP6
AKAP7
AKAP8
AKAP9 chr7:91630327 7q21.2 A > G 8/50 Ile366Val close to
bindning
domain
tolerated 4% – 24%,
36%a
pat 7
AKAP10
AKAP11 chr13:42875448 13q14.11 G > A 8/13 Asp856Asn NA tolerated 0% – 8% pat 12
AKAP12
AKAP13
AKAP14
Tumor cell fraction was determined by a clinical pathologist using blinded sample IDs
amultiple blocks from same sample
blocoregional metastasis
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Fig. 2 (See legend on next page.)
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wanted to further explore the gene expression of AKAP
gene family in the setting of breast cancer using The
Cancer Genome Atlas (TCGA) dataset (n = 522). Inter-
estingly, a significant gene expression pattern of AKAPs
was noted relative to tumor PAM50 subtypes whereby
AKAP1, 3, 7 and 8 were highly expressed in basal-like
subtypes and lower expressed in the other subtypes
(p < 0.001 Basal vs. other subgroups, ANOVA with
post-hoc Tukey, Additional file 8: Figure S5a and
Fig. 3a). Conversely, AKAP5, 9, 10, 11 and 12 all
showed lower expression in the basal-like subgroup
(p < 0.001, ANOVA with post-hoc Tukey
Additional file 8: Figure S5b and Fig. 3a). We further
investigated the gene expression of the same AKAP
gene sets in primary tumors from an independent
nested case-control cohort, consisting of 182 patients
stratified by metastatic risk with. A similar AKAP
expression pattern was found (p < 0.001, Basal vs.
other subgroups, ANOVA with post-hoc Tukey,
Additional file 8: Figure S5c, d and Fig. 3b). Finally,
in the full-sized TEX cohort 1 with metastatic lesions
(n = 120), the pattern was less distinct, however, both
AKAP1 and AKAP8 as well as AKAP5 ad AKAP9
showed a relative expression in the basal-like group
consistent with the other cohorts (Additional file 8:
Figure S5e, f and Fig. 3c).
Discussion
In this paper we report data from the exomes of pri-
mary and metastatic lesions in breast cancer. Initially
we used DNA from a small subset of patients that were
part of a larger study cohort. In order to obtain suffi-
cient DNA for exome capture we used WGA for all
samples including germline. The risk of introducing
false positive mutations using WGA prior sequence
capture was investigated by Hasmats et al. [40] who de-
scribed that the majority of false mutations were found
in low coverage areas (< 10 reads), indicating that cau-
tion should be taken, both of allelic drop-out as well as
low coverage regions due to problematic sequences.
We addressed the issues of both false positive muta-
tions and false negative discovery rates (Additional file
6: Table S3) and found low frequences of both, except
for three of the metastatic samples in cohort 1 with
high levels of false negative rates, presumably due to
low starting concentrations and allelic drop out during
amplification. We could not detect any other sources of
variability due to different sample sources in cohort 1.
We have used two different cohorts obtained at differ-
ent time points as well as different sources of tumor
material using two different but comparable bioinfor-
matic pipelines. While cohort 1 was used for initial
findings, cohort 2 was used for validation. Using two
different cohorts, separate statistics as well as separate
analytic pipelines is a methodological strength and sup-
ports our findings regarding AKAP mutations. In co-
hort 1, we report a large increase in number of
mutations for some patients. We also found a low pro-
portion of shared mutations between primary and
metastatic tumor tissue. While the average increase in
mutations in metastatic tissue was less pronounced in
cohort 2 we confirm a higher mutational load in meta-
static tumors. The contribution of APOBEC related
mutagenesis has been revealed to be increased in me-
tastases and might impact the mutational load in meta-
static tissues. Low percentage of overlapping mutations
is affected by tumor heterogeneity. Up to 70% of tumor
heterogeneity both within a primary tumor but also be-
tween primary and metastasis have been reported in
breast cancer and, with even higher discordance in
other cancers [41]. Changes in the mutational processes
and the inherent tumor heterogeneity could both lead
to a low number of shared mutations.
Here, we report for the first time that somatic muta-
tions in the AKAP gene family occur in breast cancer
and are enriched in metastatic lesions. Studies including
both primary breast cancer tumors and their corre-
sponding metastatic lesions are still rare but Lefebvre et
al. report the mutational profiles from metastases from
over 200 patients using TCGA data as primary tumor
reference [28]. In this study, mutations in the AKAP
gene family are well represented with one or more
AKAP mutations being present in 30 out of 216 patients
(14%) being compared. In total 42 nonsynonymous mu-
tations are present in 9 different AKAP genes, support-
ing our findings.
A-kinase anchoring proteins (AKAPs) are members of a
protein family acting as anchors for Protein Kinase A
(PKA) by specifically associating PKA regulatory subunits
RI and RII to cellular organelles and directing its active
signal transduction spatially and temporally via cyclic
AMP [17]. This functionality has implications for both cell
(See figure on previous page.)
Fig. 2 Gene view of AKAP mutations and AKAP protein regions and domains. Drop symbols indicating location of amino acid exchange light green:
mutation present only in metastasis; dark green: mutation present in both primary tumor and corresponding metastasis; blue: SNP reported association
with familiar breast cancer [46, 48, 66]. PKA-RI/II: protein kinase A regulatory subunit I/II; WSK: short conserved WXSXK motif in protein kinase A binding
proteins (AKAPs); ZF: Zinc finger repeats; MCM2: minichromosome maintenance complex 2 [33]; DH: Dbl homology domain (RhoGEF); PH:
Pleckstrin homology domain; Protein kinase interacting domains are provided from uniprotKB with additional domains from [32]**. EGFR interacting
domain from [63]
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motility and cell proliferation. Studies show that an altered
balance between subunit RI and RII has implications for
tumorgenesis in prostate [42], colon [43, 44] and in
addition a prognostic value in breast cancers [45]. Over-
expression of subunit RI tends to increase proliferative
mechanisms and is elevated in malignant lesions, whereas
the RII counterpart tends to upregulate apoptotic path-
ways, downregulate proliferative genes and shows a de-
creased expression in malignant cells.
In line with the function of PKA in tumorgenesis, sev-
eral of the AKAP members have been associated with can-
cer development and metastatic spread. Although only
AKAP9 has been previously reported as a recurrently mu-
tated gene in COSMIC (Catalogue of Somatic Mutations
in Cancer) database, several members of the AKAP family
have been found to be associated with both oncogenic and
tumor suppressing functions in several cancers including
breast cancer. Specific polymorphisms in AKAP10 and in
a
b
c
Fig. 3 Expression profiles of the AKAP gene family in three different cohorts, tumors ordered by PAM50 subtype, genes are orderad by hierarchial
clustering. a TCGA RNAseq expression profiles from primary tumors (n = 522). Genes are ordered by hierarchical clustering p < 0.0001 by ANOVA;
q < 0.000072. Intrinsic subtype calls for the TCGA data were taken from the original manuscript [1]. b Risk Cohort microarray expression profiles
from primary breast cancer tumors (n = 182). c Cohort 1 microarray expression profiles from metastatic lesions (n = 120)
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particular in combination with a SNP in AKAP13 were
shown to be associated with increased risk for familial
breast cancer [46]. The same polymorphism in AKAP10
(Ile646Val) (Fig. 2) was also found to be associated with
colorectal cancer risk [47]. Additionally, specific polymor-
phisms in AKAP9 are associated with increased risk in fa-
milial breast cancers [48]. AKAP12 expression is down-
regulated in various cancers summarized in [29] including
breast cancer [37] and have been suggested as a suppres-
sor of invasiveness in prostate cancer through inhibition
of the PKC-Raff/MEK/ERK pathway as well as inhibition
of VEGF-mediated neovascularization [49]. Here, two mu-
tations in AKAP12 were present in the EGFR-binding do-
main (Fig. 3), indicating a possible function in the
deregulation of EGFR signaling pathways present in ma-
lignant cells [50]. Furthermore, the down regulation of
AKAP12 is often associated with promoter hypermethyla-
tion or loss of its locus 6q24-25.2 [51]. Based on this,
AKAP12 has been suggested to have a tumor suppressing
function [49]. AKAP12 and AKAP11 was also shown to be
essential for endothelial barrier function, the latter by link-
ing cAMP signalling to adherens proteins such as VE-
cadherin and β-catenin [52]. Similarly, AKAP5 have been
shown to localize with E-cadherin and β-catenin in epithe-
lial adherens junctions stabilizing F-actin [53]. Further-
more, overexpression of AKAP5 was shown to reduce
proliferation and hyperplasia in smooth muscle cells [54].
AKAP9 has been shown to be essential for microtubuli dy-
namics at adherens junctions [55] and recently [56], dem-
onstrated that in mice with AKAP9 deficient T-cells,
antigen- dependent activation of the T-cell by TCR recyc-
ling is impaired, suggesting a possible role in tumor cell
immune surveillance (authors comment).
Taken together, AKAP 5, 9, 11 and 12 all seem to be
involved in various aspects of epithelial integrity, pre-
senting them as potential players in cell migration and
metastatic mechanisms. In our data, loss of the AKAP12
locus occurs in six out of 30 patients. In four of these,
the loss is detected in metastasis only. AKAP5 was de-
leted in two of 20 patients, both in which the lesion was
found uniquely in the metastasis (Table 4). Interestingly,
AKAP5, AKAP9, AKAP11 and AKAP12 is expressed at
lower levels in the basal-like and, less prominently in
HER2-enriched subtypes (Fig. 3a-b), the breast cancer
subtypes with highest risk of recurrence [57].
AKAP13, also named lymphoblast crisis oncogene
(AKAP-LBC) binds, and is negatively regulated by the
metastasis suppressor protein NDKA encoded by the
NM23 gene [31]. Disruption of AKAP13 mediated an-
choring of PKA decreased carcinoma cell line migration
in vitro [58]. Importantly, overexpression of the NM23-
H2 isoform was shown to downregulate nuclear receptor
peroxisome proliferator-activated receptor δ (PPAR-δ) in
human cholangiocarcinoma cells [59]. Recently it was
shown [60] that AKAP13 is essential for tamoxifen resis-
tence induced by PKA dependent phosphorylation of
ERαS305 through its direct association via ERα-binding
domain and PKA. One of the mutations in AKAP13
(D477N) found in this study, is indeed located in the
PKA-RII binding subunit of AKAP13 (Fig. 2).
AKAP4 expression is detected at high rate in various
breast cancer tumors and has been suggested as a bio-
marker for breast and prostate cancer [38]. Specifically
AKAP3 have been shown to play a role in cell migration
and invasion in ovarian cancer [39]. AKAP1 was shown to
be required for cAMP-dependent PKA mediated apoptosis
in colorectal cancer cells upon IGF1R inhibition [61].
AKAP8 is a nuclear localized protein suggested to play a
role in both DNA replication, cell cycle progression and
chromatin condensation [29, 62] and also interacts with
minichromosome maintenance protein 2 (MCM2).
Disruption of the AKAP8-MCM2 interaction abolished
DNA replication in HeLa cells [63]. In our study the
AKAP8 mutation in the metastatic lesion was located
within the MCM2-binding domain (Fig. 2).
Interestingly, in line with the findings in our study, som-
atic mutations in AKAP8 and AKAP9 were found in mul-
tiple metastases in a patient with renal cell carcinoma but
were both absent in the primary tumor [64]. Similarly, an
AKAP9 mutation was detected in circulating tumor DNA
upon relapse, but not in the primary tumor or in blood
samples prior disease progression [65]. These findings fur-
ther underscore the metastasis-specific enrichment of
AKAP mutations. AKAP mutations are highly prevalent
in most primary cancers available in The Cancer Gen-
ome Atlas data accessed through CBioportal including
CNV and point mutations (Additional file 7: Figure S4a).
Lung squamous carcinoma has the highest mutation fre-
quency with over 50% of the samples having alterations in
any of AKAP genes 1–14, including 20% point muta-
tions. In primary breast cancer almost 30% have alter-
ations including 10% point mutations. Among these,
AKAP1 and AKAP11 are altered in > 10%, including
gene expression alterations. AKAP3, 7, 8, 9, 10 and 13
are all altered in > 5% (Additional file 7: Figure S4b).
Our findings reveal that although present in 10% (3 of
30) primary tumors, AKAP mutations are much more
prevalent (40%) in the metastatic lesions (12 of 30), indi-
cating a clonal selection of certain malignant subpopula-
tions during the metastatic process.
In summary, we report that several members of the A-
kinase anchoring protein family (AKAPs) are mutated in
metastatic breast cancer lesions. We further describe
that the AKAP gene family is differently expressed in
both primary and metastatic tumors and that basal-like
tumors show an altered AKAP expression profile divid-
ing the AKAPs in one highly expressed group; AKAP1,
AKAP3, AKAP7, AKAP8 and one low group; AKAP5,
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AKAP9, AKAP10, AKAP11, AKAP12. Much of previously
reported functions of these individual AKAPs points to-
wards that this AKAP clusters indeed could reflect true
metastatic potential. The reduced expression of genes in-
volved in stabilization of adherence proteins (AKAP5, 9,
11 and 12) as well as increase expression of genes associ-
ated with poor prognosis and proliferation (AKAP3 and
AKAP8) strongly underscores the involvement of AKAP
genes during tumor growth and dissemination.
Conclusions
Several studies have reported individual AKAP genes to be
associated with cancer risk and specifically metastatic re-
lapses but no study has so far demonstrated the presence
of somatic genetic alterations in clinical metastatic sam-
ples. Here, we demonstrate that somatic mutations occurs
in a multitude of the members of the AKAP family in
breast cancer tissue, and that several of the mutations are
acquired or enriched in the metastatic corresponding
metastatic tumors. Several of these mutations do occur in
functionally relevant regions. Further, we demonstrate that
AKAP gene expression follows a subtype specific pattern
that was confirmed in three independent cohorts, pin-
pointing a subset of the AKAP members to be interesting
targets for further investigation. While conclusions regard-
ing functionality of mutations or significance of differential
AKAP gene expression, cannot be drawn here, our findings
presents a novel example of convergent mutations towards
a gene family with many reported implications in cancer
disease. Further studies will be needed to investigate the
functional role of individual AKAP genes in cancer and the
implication of differential expression in breast cancer.
Additional files
Additional file 1: Table S1. Patient table cohort 2. The study material
includes 20 patients and was collected at Karolinska University Hospital
between the years 2000 and 2011. The following inclusion criteria were
applied; metastatic adenocarcinoma; detailed clinical data available;
axillary and distant metastasis available; required amount of paraffin
embedded tissue. The study was approved by the Ethics committee at
the Karolinska Institute. (PDF 637 kb)
Additional file 2: Table S2. DNA concentrations. Complete list of DNA
concentrations after extraction from tumor- or normal tissues and blood.
For Cohort 1 total input amounts to WGA and recovered DNA amounts
after is listed. (PDF 248 kb)
Additional file 3: Figure S2. Mean coverage of whole-exome sequencing
in a) cohort 1 and b) cohort 2. b) Exome capture and sequencing was
performed by SeqWright Genomic Services (GE Healthcare, Houston, USA).
Briefly, exome capture was performed using Sure Select XT2 Human All
ExonV5 (Agilent Technologies) according to manufacturers instructions.
Paired end sequencing was performed on Illumina HiSeq 2500. Raw
sequencing reads were quality and adapter trimmed using trim_galore,
where the first 13 bases of Illumina adapter were used and stringency
parameter was set to 2. Reads having lengths less than 70 after
trimming were filtered out with their paired mates. Trimmed reads
were aligned to the human reference genome build hg19 using
bwa-mem with default parameters. The aligned reads were marked for
duplicates by Picard, realigned around known indels and base-quality
recalibrated by GATK. Somatic single nucleotide variants (SNVs) were
detected by Mutect with the high-confidence mode. Somatic short
indels were detected by Varscan2 with minimum variant allele
frequency of 0.05. Copy number alterations were detected by ADTEx/
Ascat. All pipelines and analyses were run using Anduril, a workflow
framework for scientific data analysis. (PDF 915 kb)
Additional file 4: Figures S1a and S1b. Exome-wide view of
mutations in metastatic breast cancer. Each panel (numbered by
patient ID) shows whole-exome data from one patient in several
aligned tracks, as indicated on the right. SNV: single-nucleotide
variations, shown as tick marks for COSMIC recurrent cancer genes (outer
tracks) and as density for all mutations (inner tracks). The central colored
density gradient shows major allele concordance P value between
primary and metastasis (50 SNP moving windows; blue: concordant; red:
discordant), indicating the presence of concordant loss of heterozygosity.
CNV: copy-number variation (red: deletion, blue: amplification); LOH: loss-
of-heterozygosity. The Tumorscape track shows known hotspots for
copy-number variation in breast cancer using data from Tumorscape
Copy Number Alterations Across Multiple Cancer Types Release 1.6
(Broad Institute). CNV was determined by calculating the normalized
read coverage at each SNP position for paired tumor and germline
samples, then taking the log2 of the ratio of these numbers and
recentering to zero. In Fig. 1, these measures were plotted as a moving
average across ten adjacent SNPs. LOH: loss of heterozygousity) as
major allele frequency for heterozygous SNPs on the vertical axis, with
manually called LOH regions indicated by horizontal lines (vertical axis
range 50–100%; red: significant SNP phase concordance with the paired
sample, p < 0.01 by the binomial distribution; black: not significant
(see also Additional file 3: Figure S2 a-b). Note that LOH could not be
called for some samples (metastases of P1, P2, P4 and P10) because of
low data quality. SNP phase concordance was determined using all SNPs in
the LOH region in A and recorded the major allele of each (i.e. the ‘phase’
of the LOH region). We then tested the null hypothesis that the alleles of
the corresponding SNPs in sample B was randomly distributed relative to A,
with a 50% chance of concordance at each position. This would be
expected if there were in fact no LOH in B, as the major allele would then
be determined by the random fluctuations of read coverage. Under this
model, the probability of observing k concordant calls among n SNPs is
distributed according to the Binomial distribution (k; n, p) with p = 0.5. Thus
we calculated the P value as the cumulative density of this distribution from
k to n (that is, the probability of observing as many as k concordant calls, or
more). A low P value (e.g. P < 0.01) on this test suggest that the LOH region
in A was in fact also present on B, whereas a high P (e.g. P > 0.99) value
suggests that there was LOH in B, but it was derived from the opposite
allele compared with A. Intermediate values are expected whenever there
was no LOH in sample B. The central track for each patient in Additional file 4:
Figure S1 shows this P value. (ZIP 1670 kb)
Additional file 5: Figures S3a and S3b. Estimation of LOH fraction and
tumor content. Estimation of LOH fraction and tumor content using a Beta-
Normal mixture model. Histograms show the distribution of major allele fre-
quencies (range: 50–100%) and red curves show the mixture model esti-
mated from the data. The set of SNPs called in the germline sample was
considered in the tumor sample (primary and metastasis independently).
When genomes contain regions of LOH, the distribution will be bimodal, as
illustrated in the inset (top right). The first component (closer to 50%; red in
inset) represents heterozygous SNPs in regions without LOH and was mod-
eled as a normal distribution with a mean close to 50% in a perfect sample,
but will increase towards 100% as allelic dropout increases. The second
component (closer to 100%; blue in inset) represents homozygous SNPs in
regions with LOH, was modeled as a beta distribution with two parameters
(the mean of this component should be close to 100% and increase as LOH
fraction increases and decrease as with non-cancer cell contamination. The
mixture distribution thus had four free parameters plus the mixture
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proportion, the latter representing the estimated LOH fraction of the sam-
ple. Fitting this mixture to the observations yielded estimates for LOH frac-
tion, tumor fraction and allelic dropout rate for each sample
(Additional file 3: Figure S2). Model fitting was performed using the Esti-
matedDistribution function of Mathematica 9.0 (Wolfram Research
Inc.). (ZIP 421 kb)
Additional file 6: Table S3. Control experiment. To investigate the rate
of false positive mutations as well as the loss of alleles introduced by the
amplification process we designed a control experiment as follows:
Genomic DNA from a healthy individual was extracted from whole blood
using the PAXgene Blood DNA kit (Qiagen). The DNA was of good quality
(> 58 kB fragment length) and of high concentration (> 300 ng/uL). This
DNA was diluted 1:100 and 1:1000 and 6 ng respectively 0.6 ng was
subjected to WGA, exome enriched, sequenced and analyzed as described
in (Fig. 2a) using an unamplified sample as ‘germline’ control. In the control
exome experiment with 6 ng input gDNA, we found no (zero) variant
positions, indicating that the false discovery rate was negligible when the
amount of starting material was in the range of 6 ng or more. In the control
exome experiment with 0.6 ng input gDNA, we found 27 amino acid
altering mutations that passed our SNV calling criteria. This indicates that
false positive SNVs can start to appear as the amount of input material is
reduced. We used this higher rate of false positives to estimate the false
discovery rate (FDR) in samples with input less than 6 ng. Note that no
tumor sample was amplified from less than 1.2 ng DNA. Allelic drop out or
loss of heterozygosity due to biased amplification towards one of the alleles
will be challenging to distinguish from true LOH. As expected, in the control
exomes no LOH was detected. The fraction of called LOH positions was
0.6% and 1% of all variant positions in the 6 ng and 0.6 ng control
experiments respectively, and these positions did not form continuous
regions. In most tumor samples, we could clearly distinguish regions of true
LOH, as blocks of SNPs with LOH calls. Outside these regions, any observed
LOH could be assumed to be artefactual. We therefore determined the
fraction of LOH calls in regions without signs of true LOH in the tumor
samples, as a measure of false negative calls (allelic dropout). In the primary
tumor samples we found 1.36% (0.1%- 8.3%) false negatives, whereas in the
metastatic samples this fraction was 4.88% (0%–16.25%). However, three of
the samples (metastases of patients P1, P4 and P10) were of poor quality
showing a very noisy pattern of variant allele frequencies, most likely due to
DNA degradation and low concentration. In these three samples the false
negative discovery rate could not be calculated but could be approximated
by assuming that there were no true LOH calls at all, resulting in a
conservative estimate of 43–87% false negative calls in these three samples.
We could not identify LOH independently in these samples, but we used
the SNP phase test described in (Additional file 4: Figure S1a-b) to confirm
or reject the existence of LOH alterations in the metastatic lesion
concordant with the primary tumor. Although the median false
negative SNV rate was less than 1%, the metastatic samples of three
patients (P1, P4 and P10) suffered a rate exceeding 40%, presumably
due to allelic dropout during amplification. The median false discovery
rate was 1%, and did not exceed 6% for any patient. (PDF 398 kb)
Additional file 7: Figure S4. AKAP mutations in TCGA data. a) AKAP
mutations across all cancers available through cBioPortal (TCGA,
provisional). b) AKAP mutations and gene expression alterations in Breast
Invasive Carcinoma, (TCGA, provisional). (PDF 753 kb)
Additional file 8: Figure S5. AKAP gene expression. Boxplots showing
summed expression of AKAP 8,7,3,1 and AKAPs 5,11,9,10,12 gene expression
within each PAM50 molecular subgroup, a-b; TCGA data, c-d; risk cohort, d-e;
cohort 1. P-values are indicative of ANOVA followed by post-hoc Tukey for
Basal vs. other subtypes individually. ***; p≤ 0.001, **; p≤ 0.01. (PDF 586 kb)
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